Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352346 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4352701 | 0.90 | GRIN1 (0.74) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4352698 | 0.90 | GRIN1 (0.74) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4356156 | 0.88 | DCTPP1 (0.64) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4356157 | 0.88 | DCTPP1 (0.64) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4364826 | 0.82 | GRIN1 (0.80) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4364828 | 0.82 | GRIN1 (0.80) | GRIN1GRIN2BMAPTENPP2MEN1 | |
| SCHEMBL4349885 | 0.82 | GRIN1 (0.67) | GRIN1GRIN2BMAPTENPP2KMT2A | |
| SCHEMBL4349888 | 0.82 | GRIN1 (0.67) | GRIN1GRIN2BMAPTENPP2KMT2A | |
| SCHEMBL4350265 | 0.81 | GRIN1 (0.72) | GRIN1GRIN2BMAPTENPP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | claimed |
| EP-1890695-B1 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | GRUENENTHAL GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1890695-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215758-A1 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs | ABCB1, ABCG2, SLC5A2 | GRIN1 1485/4885GRIN2B 1366/4885MAPT 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.